Copyright Reports & Markets. All rights reserved.

Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Research Report 2021

Request for Sample of this report
Buy now

1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Overview

  • 1.1 Product Overview and Scope of T-Cell & NK-Cell Engaging Bispecific Antibodies
  • 1.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Type
    • 1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Recombinant Monoclonal Antibodies
    • 1.2.3 In-House Bispecific Antibodies
  • 1.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Segment by Application
    • 1.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Comparison by Application: (2021-2027)
    • 1.3.2 Immunotherapy of Cancer
    • 1.3.3 Clinical Experiment
  • 1.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Estimates and Forecasts
    • 1.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 2016-2027
    • 1.4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales 2016-2027
    • 1.4.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region: 2016 Versus 2021 Versus 2027

2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Competition by Manufacturers

  • 2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Sites, Area Served, Product Type
  • 2.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Competitive Situation and Trends
    • 2.5.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest T-Cell & NK-Cell Engaging Bispecific Antibodies Players Market Share by Revenue
    • 2.5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario by Region

  • 3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
    • 3.3.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
    • 3.3.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
    • 3.4.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
    • 3.4.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Region
    • 3.5.1 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Region
    • 3.5.2 Asia Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
    • 3.6.1 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
    • 3.6.2 Latin America T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Sales by Country
    • 3.7.2 Middle East and Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Analysis by Type

  • 4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Type (2016-2021)
  • 4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2016-2021)
  • 4.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Type (2016-2021)

5 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Analysis by Application

  • 5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Sales Market Share by Application (2016-2021)
  • 5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2016-2021)
  • 5.3 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 AbbVie
    • 6.1.1 AbbVie Corporation Information
    • 6.1.2 AbbVie Description and Business Overview
    • 6.1.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 AbbVie Product Portfolio
    • 6.1.5 AbbVie Recent Developments/Updates
  • 6.2 Astellas Pharma
    • 6.2.1 Astellas Pharma Corporation Information
    • 6.2.2 Astellas Pharma Description and Business Overview
    • 6.2.3 Astellas Pharma T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Astellas Pharma Product Portfolio
    • 6.2.5 Astellas Pharma Recent Developments/Updates
  • 6.3 GEMoaB Monoclonals
    • 6.3.1 GEMoaB Monoclonals Corporation Information
    • 6.3.2 GEMoaB Monoclonals Description and Business Overview
    • 6.3.3 GEMoaB Monoclonals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 GEMoaB Monoclonals Product Portfolio
    • 6.3.5 GEMoaB Monoclonals Recent Developments/Updates
  • 6.4 Immunocore
    • 6.4.1 Immunocore Corporation Information
    • 6.4.2 Immunocore Description and Business Overview
    • 6.4.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Immunocore Product Portfolio
    • 6.4.5 Immunocore Recent Developments/Updates
  • 6.5 Molecular Partners
    • 6.5.1 Molecular Partners Corporation Information
    • 6.5.2 Molecular Partners Description and Business Overview
    • 6.5.3 Molecular Partners T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Molecular Partners Product Portfolio
    • 6.5.5 Molecular Partners Recent Developments/Updates
  • 6.6 Roche
    • 6.6.1 Roche Corporation Information
    • 6.6.2 Roche Description and Business Overview
    • 6.6.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Roche Product Portfolio
    • 6.6.5 Roche Recent Developments/Updates
  • 6.7 AstraZeneca
    • 6.6.1 AstraZeneca Corporation Information
    • 6.6.2 AstraZeneca Description and Business Overview
    • 6.6.3 AstraZeneca T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 AstraZeneca Product Portfolio
    • 6.7.5 AstraZeneca Recent Developments/Updates
  • 6.8 Merck & Co.
    • 6.8.1 Merck & Co. Corporation Information
    • 6.8.2 Merck & Co. Description and Business Overview
    • 6.8.3 Merck & Co. T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Merck & Co. Product Portfolio
    • 6.8.5 Merck & Co. Recent Developments/Updates
  • 6.9 Pfizer
    • 6.9.1 Pfizer Corporation Information
    • 6.9.2 Pfizer Description and Business Overview
    • 6.9.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Pfizer Product Portfolio
    • 6.9.5 Pfizer Recent Developments/Updates
  • 6.10 Eli Lilly
    • 6.10.1 Eli Lilly Corporation Information
    • 6.10.2 Eli Lilly Description and Business Overview
    • 6.10.3 Eli Lilly T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Eli Lilly Product Portfolio
    • 6.10.5 Eli Lilly Recent Developments/Updates
  • 6.11 IGM Biosciences
    • 6.11.1 IGM Biosciences Corporation Information
    • 6.11.2 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.11.3 IGM Biosciences T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 IGM Biosciences Product Portfolio
    • 6.11.5 IGM Biosciences Recent Developments/Updates
  • 6.12 Novartis
    • 6.12.1 Novartis Corporation Information
    • 6.12.2 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.12.3 Novartis T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Novartis Product Portfolio
    • 6.12.5 Novartis Recent Developments/Updates
  • 6.13 BenHealth Biopharmaceuticals
    • 6.13.1 BenHealth Biopharmaceuticals Corporation Information
    • 6.13.2 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.13.3 BenHealth Biopharmaceuticals T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 BenHealth Biopharmaceuticals Product Portfolio
    • 6.13.5 BenHealth Biopharmaceuticals Recent Developments/Updates
  • 6.14 CytomX Therapeutics
    • 6.14.1 CytomX Therapeutics Corporation Information
    • 6.14.2 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.14.3 CytomX Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 CytomX Therapeutics Product Portfolio
    • 6.14.5 CytomX Therapeutics Recent Developments/Updates
  • 6.15 Janssen
    • 6.15.1 Janssen Corporation Information
    • 6.15.2 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.15.3 Janssen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.15.4 Janssen Product Portfolio
    • 6.15.5 Janssen Recent Developments/Updates
  • 6.16 Lava Therapeutics
    • 6.16.1 Lava Therapeutics Corporation Information
    • 6.16.2 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.16.3 Lava Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.16.4 Lava Therapeutics Product Portfolio
    • 6.16.5 Lava Therapeutics Recent Developments/Updates
  • 6.17 MacroGenics
    • 6.17.1 MacroGenics Corporation Information
    • 6.17.2 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.17.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.17.4 MacroGenics Product Portfolio
    • 6.17.5 MacroGenics Recent Developments/Updates
  • 6.18 Maverick Therapeutics
    • 6.18.1 Maverick Therapeutics Corporation Information
    • 6.18.2 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.18.3 Maverick Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.18.4 Maverick Therapeutics Product Portfolio
    • 6.18.5 Maverick Therapeutics Recent Developments/Updates
  • 6.19 VBL Therapeutics
    • 6.19.1 VBL Therapeutics Corporation Information
    • 6.19.2 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.19.3 VBL Therapeutics T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.19.4 VBL Therapeutics Product Portfolio
    • 6.19.5 VBL Therapeutics Recent Developments/Updates
  • 6.20 Amgen
    • 6.20.1 Amgen Corporation Information
    • 6.20.2 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Description and Business Overview
    • 6.20.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.20.4 Amgen Product Portfolio
    • 6.20.5 Amgen Recent Developments/Updates

7 T-Cell & NK-Cell Engaging Bispecific Antibodies Manufacturing Cost Analysis

  • 7.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of T-Cell & NK-Cell Engaging Bispecific Antibodies
  • 7.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Distributors List
  • 8.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Customers

9 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Dynamics

  • 9.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Trends
  • 9.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Drivers
  • 9.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
  • 9.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints

10 Global Market Forecast

  • 10.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Type (2022-2027)
  • 10.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Application (2022-2027)
  • 10.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of T-Cell & NK-Cell Engaging Bispecific Antibodies by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of T-Cell & NK-Cell Engaging Bispecific Antibodies by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Recombinant Monoclonal Antibodies
    In-House Bispecific Antibodies

    Segment by Application
    Immunotherapy of Cancer
    Clinical Experiment

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    AbbVie
    Astellas Pharma
    GEMoaB Monoclonals
    Immunocore
    Molecular Partners
    Roche
    AstraZeneca
    Merck & Co.
    Pfizer
    Eli Lilly
    IGM Biosciences
    Novartis
    BenHealth Biopharmaceuticals
    CytomX Therapeutics
    Janssen
    Lava Therapeutics
    MacroGenics
    Maverick Therapeutics
    VBL Therapeutics
    Amgen

    Buy now